Skip to main content
Premium Trial:

Request an Annual Quote

Santaris Regains Ownership of Cancer Programs Licensed to Enzon

Premium

Santaris Pharma said this week that partner Enzon has returned the rights to all of the data and intellectual property related to the locked nucleic acid drugs the companies were developing under a long-term partnership in cancer.

Santaris said it will also receive an undisclosed amount of money as part of the arrangement, and did not provide reasons behind Enzon's decision. None of the products the companies were working on were microRNA-related.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.